695 related articles for article (PubMed ID: 30033639)
1. Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
Saraceni F; Beohou E; Labopin M; Arcese W; Bonifazi F; Stepensky P; Aljurf M; Bruno B; Pioltelli P; Passweg J; Sociè G; Santarone S; Yakoub-Agha I; Lanza F; Savani BN; Mohty M; Nagler A;
Am J Hematol; 2018 Oct; 93(10):1211-1219. PubMed ID: 30033639
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Saraceni F; Labopin M; Brecht A; Kröger N; Eder M; Tischer J; Labussière-Wallet H; Einsele H; Beelen D; Bunjes D; Niederwieser D; Bochtler T; Savani BN; Mohty M; Nagler A
J Hematol Oncol; 2019 Apr; 12(1):44. PubMed ID: 31023346
[TBL] [Abstract][Full Text] [Related]
3. Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.
Pagliardini T; Castagna L; Harbi S; Porta MD; Rey J; Fürst S; Bramanti S; Saillard C; Legrand F; Maisano V; Faucher C; Granata A; Hospital MA; Lining W; Weiller PJ; Calmels B; Charbonnier A; Lemarie C; Chabannon C; Vey N; Mokart D; Blaise D; Devillier R
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1803-1809. PubMed ID: 31128325
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia.
Jiang Y; Fang X; Sui X; Liu X; Li Y; Wang X; Xu H; Zhang L; Wang X
Exp Clin Transplant; 2018 Dec; 16(6):736-744. PubMed ID: 29790457
[TBL] [Abstract][Full Text] [Related]
5. Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party.
El-Cheikh J; Labopin M; Al-Chami F; Bazarbachi A; Angelucci E; Santarone S; Bonifazi F; Carella AM; Castagna L; Bruno B; Iori AP; La Nasa G; Savani B; Nagler A; Mohty M
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):296-304. PubMed ID: 32081702
[TBL] [Abstract][Full Text] [Related]
6. Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia.
Raida L; Tucek P; Faber E; Vondrakova J; Rusinakova Z; Skoumalova I; Hubacek J; Jarosova M; Katrincsakova B; Pikalova Z; Kurfurst P; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Dec; 155(4):327-32. PubMed ID: 22336644
[TBL] [Abstract][Full Text] [Related]
7. Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine.
Giannotti F; Labopin M; Shouval R; Sanz J; Arcese W; Angelucci E; Sierra J; Santasusana JR; Santarone S; Benedetto B; Rambaldi A; Saccardi R; Blaise D; Carella MA; Rocha V; Baron F; Mohty M; Ruggeri A; Nagler A
J Hematol Oncol; 2018 Aug; 11(1):110. PubMed ID: 30165887
[TBL] [Abstract][Full Text] [Related]
8. Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia.
Bazarbachi A; Labopin M; Blaise D; Forcade E; Socié G; Berceanu A; Angelucci E; Bulabois CE; Kröger N; Rambaldi A; Ceballos P; Mielke S; El Cheikh J; Yakoub-Agha I; Savani B; Spyridonidis A; Nagler A; Mohty M
Bone Marrow Transplant; 2021 Mar; 56(3):622-634. PubMed ID: 33020591
[TBL] [Abstract][Full Text] [Related]
9. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
10. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study.
Sora F; Grazia CD; Chiusolo P; Raiola AM; Bregante S; Mordini N; Olivieri A; Iori AP; Patriarca F; Grisariu S; Terruzzi E; Rambaldi A; Sica S; Bruno B; Angelucci E; Bacigalupo A
Biol Blood Marrow Transplant; 2020 Apr; 26(4):698-703. PubMed ID: 31875522
[TBL] [Abstract][Full Text] [Related]
12. Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
Modi D; Singh V; Kim S; Ayash L; Deol A; Ratanatharathorn V; Uberti JP
Ann Hematol; 2021 Apr; 100(4):969-978. PubMed ID: 33594448
[TBL] [Abstract][Full Text] [Related]
13. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.
Liu H; Zhai X; Song Z; Sun J; Xiao Y; Nie D; Zhang Y; Huang F; Zhou H; Fan Z; Tu S; Li Y; Guo X; Yu G; Liu Q
J Hematol Oncol; 2013 Feb; 6():15. PubMed ID: 23394705
[TBL] [Abstract][Full Text] [Related]
14. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
15. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
[TBL] [Abstract][Full Text] [Related]
16. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.
Lee JH; Joo YD; Kim H; Ryoo HM; Kim MK; Lee GW; Lee JH; Lee WS; Park JH; Bae SH; Hyun MS; Kim DY; Kim SD; Min YJ; Lee KH
J Clin Oncol; 2013 Feb; 31(6):701-9. PubMed ID: 23129746
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia.
Uberti JP; Agovi MA; Tarima S; Haagenson M; Gandham S; Anasetti C; Baker KS; Bolwell BJ; Bornhauser M; Chan KW; Copelan E; Davies SM; Finke J; Hale GA; Kollman C; McCarthy PL; Ratanatharathorn V; Ringdén O; Weisdorf DJ; Rizzo JD
Bone Marrow Transplant; 2011 Jan; 46(1):34-43. PubMed ID: 20400989
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies.
Khalil MMI; Messner HA; Lipton JH; Kim DD; Viswabandya A; Thyagu S; Deotare U; Michelis FV
Ann Hematol; 2018 Oct; 97(10):1975-1985. PubMed ID: 29947975
[TBL] [Abstract][Full Text] [Related]
20. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
